Discussion
tumor, tumors
TUMOR, TUMORS, SOLID TUMORS
Senaparib was well tolerated, had good PK properties, and showed encouraging signs of antitumor activity in Chinese patients with previously treated, advanced solid tumors, as well as in a subpopulation of patients harboring BRCAThe safety profile of senaparib in the Chinese patients in this study was generally consistent with those of currently approved PARP inhibitors,PARP inhibitors have demonstrated efficacy in a variety of solid tumors, with particular benefits in tumors harboring alterations in DNA-damage repair genes, such as BRCAPARP-inhibitor-based combination therapies, including chemotherapy, other targeted therapies, and radiotherapy, are currently under investigation for solid tumors, toward achieving an additive or synergistic outcome.The single-arm, phase I, dose-escalation/expansion design of this study represents a limitation of this analysis. The small number of patients was not evenly distributed across the dose groups, there was no comparator arm, and much of the data was obtained at doses other than the RP2D. In addition, most of the patients had advanced tumors after failure of multiple lines of treatment and were not screened for tumor markers.